To include your compound in the COVID-19 Resource Center, submit it here.

FDA grants breakthrough designation to Alnylam's FAP candidate

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said FDA granted breakthrough therapy designation to patisiran (ALN-TTR02) to treat familial amyloidotic polyneuropathy (FAP), a

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE